Lindahl advises Senzime AB on a directed new share issue of SEK 100 million
Lindahl has advised Senzime AB (publ) in connection with a directed new share issue that will provide the company with SEK 100 million before transaction costs.
The subscription price was determined through an accelerated bookbuilding process, with Carnegie Investment Bank acting as financial adviser.
About Senzime
Senzime AB is a company listed on Nasdaq Stockholm that develops and markets CE and FDA approved monitoring systems for patients undergoing anaesthesia.
Lindahl's team consisted of Mattias Prage, Andreas Mellberg and Michaela Larsson.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatMichaela Larsson
Associate | AdvokatCarousel items
-
Cases and transactions
9/14/2026
Lindahl has advised Pareto Securities AB on a rights issue
Lindahl acted as deal counsel to Pareto Securities AB in connection with a rights issue of shares in Teneo AI as part of the company’s refinancing.
-
Knowledge
9/11/2026
Key provisions of the Cyber Resilience Act (CRA) become applicable on 11 September 2026
Key provisions of the Cyber Resilience Act (CRA) come into effect on 11 September 2026. Read about the new reporting requirements and what companies need to do.
-
News articles
9/4/2026
Mikael Wärnsby represents Sweden at international conference on new nuclear power
Mikael Wärnsby represented Sweden at EFELA’s international conference on licensing and regulatory frameworks for new nuclear power in Europe.
-
Portraits
7/3/2026
Jesper on business-oriented legal advice in energy: "It is not enough for the advice to be correct"
Lindahl's energy team is recognised in Legal 500 for combining deep regulatory expertise with broad commercial legal experience – find out how they support clients in a rapidly evolving sector.
-
Read more news and insights?
